Specifically, Harel et al., in 143 stage IIIB-IV NSCLC patients treated with anti-PD-(L)1 alone or in combination with chemotherapy, found a greater increase in IL-6 in non-responders than responders (p < 0.001) [31]. Here, IL6 is linked to non-small cell lung carcinoma.